- The molecular genetic basis of ovarian cancer and its roadmap towards a better treatmentE Despierre
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium
Gynecol Oncol 117:358-65. 2010..Recently, high-resolution genomic maps generated by genome-wide SNP analyses and novel sequencing technologies, have started to dissect the genetic basis of ovarian cancer...
- Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapyE Despierre
Gynecologic Oncology and Leuven Cancer Institute, University Hospitals Leuven, Department of Oncology, KU Leuven, Belgium
Gynecol Oncol 130:192-9. 2013..We evaluated whether chemotherapy modified FRA expression in non-mucinous epithelial ovarian (EOC) and endometrial carcinoma (EC)...
- Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?E Despierre
Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
Int J Gynecol Cancer 16:273-7. 2006..The documentation of chemosensitivity might enable the clinician to select a subpopulation of patients with widespread SEC that might benefit from interval debulking surgery...